How Long Does Tirzepatide Stay in Your System?

The common misconception: that tirzepatide clears after one week because it's dosed weekly

Because tirzepatide is injected once a week, many people assume it behaves like a seven-day drug, in one Monday, gone by the next. It doesn't work that way. The weekly schedule matches the medicine's approximate therapeutic window, not its elimination speed. The two are different things.

Tirzepatide's half-life sits at around five days. That means after seven days, you still have a meaningful amount in your system, even if the next dose is due. With regular weekly dosing, concentrations don't swing dramatically; they build gradually toward a steady state over the first few weeks, then level off. That stable plateau is part of why the medicine's appetite-suppressing effect tends to become more consistent as treatment progresses rather than feeling sharply on-then-off between injections.

The five-day half-life is documented in the medicine's summary of product characteristics. If you want to understand how long tirzepatide is in your system at each stage of treatment, that page walks through the accumulation and washout phases in detail. After five half-lives (roughly 25 days, or just under four weeks), concentrations fall to below five per cent of their peak. For practical purposes, prescribers treat clearance as complete around four to five weeks after the last dose. So if you stop tirzepatide, you're not clear of it after one week. Worth knowing.

What the clearance window actually affects

This isn't just pharmacology trivia. The five-week clearance window is clinically significant in a handful of situations.

Surgery and procedures: NHS England advises telling your healthcare team, including the anaesthetist, that you're taking tirzepatide before any surgical procedure. Gastric emptying is slowed by this medicine, which affects anaesthetic safety. That conversation needs to happen with enough lead time, and your prescriber can advise on timing based on your procedure date.

If you're planning a procedure around a holiday or a bank holiday (when the usual weekly order rhythm shifts) it's worth flagging that to our team early rather than adjusting doses alone. Our prescribers are available seven days a week for exactly this kind of question.

Oral contraceptives: tirzepatide can reduce absorption of the pill in the first four weeks of treatment and after each dose increase. NHS guidance recommends adding a non-oral method during those windows. That interaction persists while meaningful drug levels remain, so it's relevant beyond the last dose too. The NHS's guidance on weight-management injections covers this in detail, and it's worth reading if this applies to you.

Trying to conceive: tirzepatide is not recommended during pregnancy or while breastfeeding. The MHRA advises using effective contraception while on treatment and allowing an appropriate clearance period before attempting conception. Your prescriber will give specific guidance; the five-week window is the general starting point in the medical literature, but clinical advice should always take precedence.

How steady-state accumulation affects what you feel week to week

Understanding clearance also helps explain the early weeks of treatment. When you start on the lowest dose (the initial 2.5mg pen, which exists to let your digestive system adjust, not to drive significant weight loss) tirzepatide hasn't yet reached a steady state. Levels are building. That's partly why side effects, typically gastrointestinal in nature, can be more noticeable in the first weeks then settle as the body adapts and concentrations stabilise.

Once a steady state is established across several weeks of consistent weekly dosing, the concentration profile between doses becomes relatively flat. Missing a dose, by contrast, does mean drug levels begin to fall meaningfully before the next injection is due, and our page on how long tirzepatide lasts in your system explains what that decline looks like and why timing matters. The prescribing guidance covers what to do in that situation; the Patient Information Leaflet that comes with every pen is the right reference, not general advice online.

For a fuller picture of how this medicine behaves over its therapeutic lifetime (including how long before noticeable effects typically appear) our page on how long Mounjaro takes to work covers the clinical trajectory from first dose to peak effect. For the specific question of duration in the system framed around the Mounjaro brand name, how long Mounjaro stays in your system runs through the same underlying pharmacokinetics. Both are worth reading alongside this page.

Tirzepatide is the active ingredient in Mounjaro; the half-life data applies equally whether you see the medicine referred to by its brand or its generic name. You can read more about the treatment itself on our Mounjaro overview page.

What this means if you're considering starting or pausing treatment

If you're wondering about the five-week window because you're thinking about starting tirzepatide, the clearance timeline is reassuring in one sense: should the medicine not suit you, it isn't permanent. Drug levels fall predictably, and your prescriber can advise on what to expect during the washout period.

If you're already on treatment and considering a pause, the key point is that appetite regulation tends to reduce as levels fall. Weight regain without appropriate diet and activity support is well documented once GLP-1-type medicines clear the system. That's not a reason to stay on treatment indefinitely without review; it's a reason to plan any pause with a prescriber rather than stopping unilaterally.

Pricing and what a supervised private treatment programme covers are set out on our Mounjaro cost page, including what's included in a single transparent price. If you'd like to understand whether tirzepatide is clinically appropriate for you, our prescribers review consultations the same day, you can check your eligibility here. The NHS's patient-level page on tirzepatide is also a solid reference for the medicine's basic pharmacology.